Broadwood Partners, L.P. Buys 521,739 Shares of Oncocyte (NASDAQ:IMDX) Stock

Oncocyte Corp (NASDAQ:IMDX) major shareholder Broadwood Partners, L.P. purchased 521,739 shares of the stock in a transaction dated Tuesday, February 10th. The stock was acquired at an average cost of $5.75 per share, with a total value of $2,999,999.25. Following the transaction, the insider directly owned 11,931,839 shares in the company, valued at approximately $68,608,074.25. This trade represents a 4.57% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Oncocyte Price Performance

IMDX stock traded down $0.15 on Thursday, hitting $5.58. 124,714 shares of the company’s stock were exchanged, compared to its average volume of 47,703. The stock’s 50 day simple moving average is $6.38. Oncocyte Corp has a 12-month low of $2.21 and a 12-month high of $8.51.

Oncocyte (NASDAQ:IMDX) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.34) earnings per share for the quarter. Oncocyte had a negative net margin of 1,380.69% and a negative return on equity of 983.30%. The firm had revenue of $0.26 million for the quarter.

Analyst Ratings Changes

A number of equities analysts recently weighed in on IMDX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Oncocyte in a research report on Monday, December 29th. Wall Street Zen raised shares of Oncocyte to a “hold” rating in a research report on Saturday, November 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Oncocyte currently has an average rating of “Sell”.

Oncocyte Company Profile

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.